On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
Similar Posts
Platinum 69000 Rhino 69 contains hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Platinum 69000 Rhino 69, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.LOVION Chocolate with Ginseng for Men may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use LOVION Chocolate with Ginseng for Men, a product promoted and sold for sexual enhancement on various websites, including lovionusa.com, and possibly in some retail stores.Alembic Pharmaceuticals Limited – 11/10/2021
Alembic Pharmaceuticals Limited – 11/10/2021. Country: India. Record Type: 483BlendHouse. Reading, PA. EIR issued 06/09/2022
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 06/09/2022
Short Title (70 char) BlendHouse. Reading, PA. EIR issued 06/09/2022
FEI Number 3015728839
Firm Name BlendHouse
Record Type EIR
State PA
Establishment Type ManufacturerShiva Analyticals Private Limited – 707857 – 07/23/2025
CGMP/Finished Pharmaceuticals/AdulteratedFDA Publishes Filing Checklists to Prevent Submission Delays
The U.S. Food and Drug Administration today made public filing checklists used internally by Center for Drug Evaluation and Research (CDER) staff to determine if a submitted application is complete and reviewable.